• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·205470.KQ
Share

Humasis Co. Ltd. Stocks

₩ 2340Last Updated 23.06.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

₩ 39.13M

₩ 2340
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Humasis Co. Ltd. is a South Korean company, established in 2000 and based in Anyang, that focuses on the development, manufacturing, and global distribution of in-vitro diagnostic products. These diagnostic tools are designed to detect various markers, including those for cardiac health, fertility hormones, infectious diseases, tumor indicators, and cotinine, and are suitable for use in both home and laboratory settings. Their offerings include consumer-friendly self-tests for pregnancy and ovulation, the Hubi-Quan Pro – an integrated device that quickly provides quantifiable results from membrane-based lateral flow immunochromatographic assays – and a broad range of other rapid diagnostic kits.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is trading at neutral levels on P/FCF

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.06.2026 07:00

Alphabet will be added to the Dow Jones Blue Chip Index. Its stock price has doubled over the past year

24.06.2026 01:47

The boom in the prediction market has prompted Meta to create its own app — NYT

24.06.2026 01:09

The Nasdaq fell 2%, with volatility hitting a two-year high: a look back at the day's sell-off in the tech sector

24.06.2026 00:50

The dollar rose to its highest level since November: Traders are betting on a Fed rate hike

23.06.2026 23:45

Cathie Wood's company bought SpaceX shares on the day the stock fell 16%. Should you do the same?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026